INREBIC (fedratinib dihydrochloride)
ANTINEOPLASTIC - JANUS KINASE (JAK) INHIBITORS · MYELOFIBROSIS
CELGENE/BMS
Drug class
Antineoplastic - FMS-like Tyrosine Kinase (FLT) Inhibitor
The therapeutic class "Antineoplastic - FMS-like Tyrosine Kinase (FLT) Inhibitor"—commonly designated in clinical and formulary compendia as FLT3 inhibitors—encompasses targeted antineoplastic agents designed to inhibit the FMS-like tyrosine kinase receptor family. Read more about Antineoplastic - FMS-like Tyrosine Kinase (FLT) Inhibitor
1 drugs in this class 1 manufacturers
Drugs in Antineoplastic - FMS-like Tyrosine Kinase (FLT) Inhibitor
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - FMS-like Tyrosine Kinase (FLT) Inhibitor preselected. Add indication or manufacturer filters there.
The therapeutic class "Antineoplastic - FMS-like Tyrosine Kinase (FLT) Inhibitor"—commonly designated in clinical and formulary compendia as FLT3 inhibitors—encompasses targeted antineoplastic agents designed to inhibit the FMS-like tyrosine kinase receptor family.
These small-molecule inhibitors function primarily by blocking aberrant FLT3 receptor tyrosine kinase signaling, thereby arresting downstream proliferative cascades and inducing apoptosis in malignant cells harboring constitutive kinase activation.
The principal therapeutic indication for this drug class is hematologic malignancy, most notably acute myeloid leukemia (AML) characterized by activating *FLT3* mutations such as internal tandem duplications (ITD) or tyrosine kinase domain (TKD) alterations.
Approved agents within this category, including gilteritinib, midostaurin, and quizartinib, serve critical roles across frontline, maintenance, and relapsed or refractory AML management settings.
-
kaiserpermanente.org
The therapeutic class "Antineoplastic - FMS-like Tyrosine Kinase (FLT) Inhibitor"—commonly designated in clinical and formulary compendia as FLT3 inhibitors—encompasses targeted antineoplastic agents designed to inhibit the FMS-like tyrosine kinase receptor family Approved agents within this category, including gilteritinib, midostaurin, and quizartinib, serve critical roles across frontline, maintenance, and relapsed or refractory AML management settings
-
cancer.gov
The therapeutic class "Antineoplastic - FMS-like Tyrosine Kinase (FLT) Inhibitor"—commonly designated in clinical and formulary compendia as FLT3 inhibitors—encompasses targeted antineoplastic agents designed to inhibit the FMS-like tyrosine kinase receptor family
-
cancer.gov
These small-molecule inhibitors function primarily by blocking aberrant FLT3 receptor tyrosine kinase signaling, thereby arresting downstream proliferative cascades and inducing apoptosis in malignant cells harboring constitutive kinase activation
-
cancer.gov
These small-molecule inhibitors function primarily by blocking aberrant FLT3 receptor tyrosine kinase signaling, thereby arresting downstream proliferative cascades and inducing apoptosis in malignant cells harboring constitutive kinase activation
-
nih.gov
The principal therapeutic indication for this drug class is hematologic malignancy, most notably acute myeloid leukemia (AML) characterized by activating *FLT3* mutations such as internal tandem duplications (ITD) or tyrosine kinase domain (TKD) alterations Approved agents within this category, including gilteritinib, midostaurin, and quizartinib, serve critical roles across frontline, maintenance, and relapsed or refractory AML management settings
-
cancer.gov
The principal therapeutic indication for this drug class is hematologic malignancy, most notably acute myeloid leukemia (AML) characterized by activating *FLT3* mutations such as internal tandem duplications (ITD) or tyrosine kinase domain (TKD) alterations
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.